UCB's Global Corporate Website



In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.


In the US, BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

Other countries

For availability of Briviact® in other countries, please consult our local websites.